Cook S D, Devereux C, Troiano R, Bansil S, Zito G, Sheffet A, Jotkowitz A, Rohowsky-Kochan C, Dowling P C
Department of Neurosciences, University of Medicine and Dentistry of New Jersey, Newark, USA.
Acta Neurol Scand. 1995 Jan;91(1):22-7. doi: 10.1111/j.1600-0404.1995.tb05838.x.
Total lymphoid irradiation (TLI) has been reported to delay deterioration in patients with progressive multiple sclerosis and other autoimmune disorders. METHODS--In an open trial, the effect of TLI combined with a one year course of low dose prednisone was compared to the effect of sham TLI and TLI only in a prior double-blind study of patients with progressive multiple sclerosis. RESULTS--Twenty-seven patients receiving TLI combined with corticosteroids had significantly greater lymphocytopenia in the year post-therapy than those receiving TLI only or sham TLI and Kaplan Meier product-limit survival analysis showed significantly less progression in the TLI plus steroid group over 4 years of follow-up. No difference in lymphocytopenia or progression was found with TLI plus corticosteroid therapy when the spleen was removed from the field of irradiation. CONCLUSION--These results lend further support to the hypothesis that TLI may be effective in progressive MS, and indicates that adding low-dose prednisone may enhance this effect. The study also suggests that TLI may be equally effective whether or not the spleen is irradiated.
据报道,全身淋巴照射(TLI)可延缓进行性多发性硬化症和其他自身免疫性疾病患者的病情恶化。方法——在一项开放试验中,将TLI联合为期一年的低剂量泼尼松治疗的效果,与假TLI以及仅在先前一项针对进行性多发性硬化症患者的双盲研究中使用TLI的效果进行比较。结果——27例接受TLI联合皮质类固醇治疗的患者在治疗后一年内的淋巴细胞减少程度明显高于仅接受TLI或假TLI治疗的患者,并且Kaplan Meier乘积限生存分析显示,在4年的随访中,TLI加类固醇组的病情进展明显较少。当脾脏不在照射范围内时,TLI加皮质类固醇治疗在淋巴细胞减少或病情进展方面没有差异。结论——这些结果进一步支持了TLI可能对进行性多发性硬化症有效的假设,并表明添加低剂量泼尼松可能会增强这种效果。该研究还表明,无论是否照射脾脏,TLI可能同样有效。